37758 Federal Register / Vol. 86, No. 134 / Friday, July 16, 2021 / Notices 

consider issuing guidance describing 

best practices for advancing cultural 

competency, language access, and 

sensitivity toward AAPIs in the context 

of the federal government’s COVID–19 

response, including best practices set 

forth by public health organizations and 

experts for mitigating racially 

discriminatory language in describing 

the COVID–19 pandemic. OMH is 

leading a Departmental response to the 

memorandum. In accordance with this 

memorandum, OMH seeks to obtain 

information that may become part of or 

inform guidance to be issued regarding 

best practices. 

II. Definitions 

For the purposes of this RFI, the 

following working definitions apply. 

Best practices—A practice supported 

by evidence indicating effectiveness in 

advancing cultural competence, 

language access or sensitivity toward 

AAPIs in the context of the COVID–19 

response, generally demonstrated 

through systematic review, research, 

evaluation or practice-based evidence. 

Practices could include interventions, 

programs, strategies, policies, 

procedures, processes or other activities. 

COVID–19 response—Federal 

activities including, but not limited to: 

• Data collection, utilization and 

reporting 

• Allocation of personal protective 

equipment (PPE), tests, vaccines, 

therapeutics and other resources 

• Enforcement of anti-discrimination 

and HIPAA requirements pertaining 

to availability and access to COVID– 

19 care and treatment 

• Assistance to individuals and families 

experiencing disproportionate 

economic or health effects from 

COVID–19 

• Training and placement of contact 

tracers and other workers 

• Outreach related to vaccine trust and 

uptake, public health measures/ 

prevention, testing, or other 

mitigation measure 

III. Questions 

• What specific best practices in the 

areas listed below should be included in 

federal guidance? Please describe the 

best practice(s), evidence of its 

effectiveness, and how it has been 

applied (or could be applied) to COVID– 

19 response activities. 

Æ Advancing cultural competency 

toward AAPIs 

Æ Advancing language access for AAPIs 

Æ Advancing sensitivity toward AAPIs 

Æ Mitigating racially discriminatory 

language against AAPIs 

Æ Practices that apply the National 

Standards for Culturally and 

Linguistically Appropriate Services in 

Health and Health Care (National 

CLAS Standards). 

• What sources/resources should 

HHS use to identify additional best 

practices in these areas? 

• What considerations should be 

made in the content, audiences and 

format for best practices guidance 

products, particularly to support 

implementation? 

• How should the best practices 

guidance be disseminated (e.g., 

mechanisms, audiences)? 

• Beyond issuing best practices 

guidance, how can HHS support 

implementation of the best practices? 

Dated: July 12, 2021. 

Juliet Bui, 

Public Health Advisor, Office of Minority 

Health. 

[FR Doc. 2021–15168 Filed 7–15–21; 8:45 am] 

BILLING CODE 4150–29–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Endocrinology and Reproduction. 

Date: August 5, 2021. 

Time: 12:00 p.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Telephone Conference 

Call). 

Contact Person: Dianne Hardy, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6175, 

MSC 7892, Bethesda, MD 20892, 301–435– 

1154, dianne.hardy@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: July 12, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–15119 Filed 7–15–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Neurodevelopment, 

Neurodegeneration, Neuroimmunology, 

Infections Diseases and Brain Tumors. 

Date: July 29, 2021. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Pat Manos, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5200, 

MSC 7846, Bethesda, MD 20892, 301–408– 

9866, manospa@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: July 12, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–15120 Filed 7–15–21; 8:45 am] 

BILLING CODE 4140–01–P 


jbell on DSKJLSW7X2PROD with NOTICES